Intranasal Glucagon Treats Hypoglycemia in Type 1 Diabetes

This article originally appeared here.
Share this content:
Intranasal Glucagon Treats Hypoglycemia in Type 1 Diabetes
Intranasal Glucagon Treats Hypoglycemia in Type 1 Diabetes

MONDAY, Dec. 21, 2015 (HealthDay News) -- For patients with type 1 diabetes, intranasal glucagon is effective for treating insulin-induced hypoglycemia, according to a study published online Dec. 17 in Diabetes Care.

Michael R. Rickels, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues compared needle-free intranasal glucagon preparation with intramuscular glucagon for treatment of insulin-induced hypoglycemia in a randomized crossover noninferiority trial. Participants included 75 adults (mean age, 33 years; median diabetes duration, 18 years) with type 1 diabetes at eight clinical centers.

The researchers found that the mean plasma glucose at time of glucagon administration was 48 ± 8 mg/dL at the intranasal visits and 49 ± 8 mg/dL at the intramuscular visits. All but one intranasal visit (98.7 percent) and all intramuscular visits (100 percent) met success criteria (increase in plasma glucose to ≥70 mg/dL or ≥20 mg/dL from the glucose nadir within 30 minutes after receiving glucagon). For intranasal and intramuscular preparation, the mean time to success was 16 and 13 minutes, respectively (P < 0.001). Head/facial discomfort was reported during 25 and 9 percent of intranasal and intramuscular dosing visits, respectively; nausea occurred in 35 and 38 percent of visits, respectively.

"Intranasal glucagon was highly effective in treating insulin-induced hypoglycemia in adults with type 1 diabetes," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Locemia Solutions, which funded the study and provided the intranasal glucagon product.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »